Eli Lilly said Wednesday it is suing six companies selling versions of its experimental weight-loss drug retatrutide, calling it the beginning of a concerted effort to crack down on a vast illicit ...

Eli Lilly is suing six entities that it alleges are selling black market versions of its experimental weight-loss drug retatrutide. Lilly’s lawsuits target U.S. entities selling illegal retatrutide ...

Mounjaro sales jump 91% driven by international strength Higher-margin sales of blockbuster GLP-1 drugs offset lower prices Lilly narrows 2026 adjusted EPS forecast after deal-related charges Shares ...

Eligibility definitions differ across reports, particularly whether prior failure on highest approved antiobesity dose is required versus documenting discussion of all standard treatments. A one-off ...

Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly & Co. to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed ...

Eli Lilly is set to release its second-quarter 2026 earnings report on Aug. 5. Here’s Morningstar’s take on what to look for in Lilly’s earnings and the outlook for its stock. With its 2-star rating, ...

Novo Nordisk sued competitor Eli Lilly on Tuesday, alleging the drugmaker engaged in false advertising by claiming its GLP-1 drugs are superior to Novo's. The lawsuit accuses Eli Lilly of misleading ...

Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Indianapolis-based Eli Lilly and Company gave an unidentified 79-year-old man exclusive access to its experimental obesity and diabetes drug, according to reporting by the life sciences media ...

When Dave Ricks became chief executive officer of Eli Lilly & Co. in 2017, he was facing an industry under siege. Americans held drug companies in lower esteem than airlines, law firms and even the ...

It’s a sign of the times that this year’s American Diabetes Association (ADA) Scientific Sessions meeting in New Orleans featured more chatter on obesity drugs and pipeline programs than those ...